AstraZeneca and Daiichi Sankyo have secured U.S. Food and Drug Administration approval for ENHERTU, also known as fam-trastuzumab deruxtecan-nxki, across two new HER2-positive early breast cancer indications. The antibody drug conjugate is now cleared for neoadjuvant use before surgery in Stage II or Stage III disease and for adjuvant use after surgery in patients with residual invasive disease following HER2-targeted and taxane-based treatment.
Why ENHERTU’s move into early breast cancer changes the ADC conversation
The significance of these approvals is not simply that ENHERTU has gained more label breadth. The more important shift is that an antibody drug conjugate already central to metastatic HER2-positive breast cancer is now moving into treatment settings where the therapeutic goal is cure rather than disease control. That changes how clinicians, payers, and regulators may evaluate the balance between deeper response, recurrence prevention, and long-term safety.
For years, antibody drug conjugates have been viewed largely as powerful oncology tools for later-line cancer, where higher toxicity may be accepted because disease has already advanced. ENHERTU’s expansion into neoadjuvant and adjuvant HER2-positive early breast cancer pushes the category into a more sensitive zone. In early disease, patients may have a longer life expectancy, and any incremental safety burden receives sharper scrutiny. A therapy does not merely need to work. It needs to improve outcomes enough to justify exposing potentially curable patients to a potent ADC payload.
This is why the approvals matter strategically for AstraZeneca and Daiichi Sankyo. ENHERTU is no longer only a metastatic breast cancer franchise with broader HER2-directed ambitions. It is becoming a sequencing asset across the HER2-positive breast cancer pathway. If adoption follows the clinical data, the drug could influence how oncologists think about treatment intensity before surgery, how they manage residual disease after surgery, and how they reserve or replace established HER2-directed standards.
What DESTINY-Breast11 suggests about pre-surgical treatment intensity
In the neoadjuvant setting, the approval rests on DESTINY-Breast11, where ENHERTU followed by a taxane, trastuzumab and pertuzumab produced a pathologic complete response rate of 67.3%, compared with 56.3% for dose-dense doxorubicin and cyclophosphamide followed by trastuzumab and pertuzumab. The absolute improvement of 11.2 percentage points gives clinicians a clear efficacy signal in a setting where pathologic complete response is treated as an important early indicator of long-term outcome.
The clinical appeal is easy to understand. HER2-positive early breast cancer can be aggressive, and the period before surgery gives oncologists an opportunity to test tumor sensitivity while disease is still localized. A higher pathologic complete response rate can help reshape confidence in the treatment plan, especially for patients at higher risk of recurrence. For a drug like ENHERTU, the neoadjuvant approval also helps reposition ADCs from post-progression therapy to early intervention.
The unresolved question is durability. Pathologic complete response is meaningful, but clinicians will still watch event-free survival and overall survival maturity closely. At the time of the analysis, event-free survival and overall survival events were limited, which means the early response advantage will need to translate into longer-term risk reduction for the regimen to fully reshape practice. The approval provides regulatory validation, but clinical confidence will deepen only as follow-up data clarify whether the stronger pre-surgical response changes recurrence patterns over time.
Why DESTINY-Breast05 may have the bigger near-term practice impact
The adjuvant approval may carry a more immediate treatment-sequencing implication because it addresses patients with residual invasive disease after neoadjuvant therapy. This is a clinically important group because residual disease signals that the cancer did not fully respond to pre-surgical treatment, leaving patients at higher risk of recurrence. In DESTINY-Breast05, ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared with trastuzumab emtansine, with three-year invasive disease-free survival of 92.4% versus 83.7%.
That result directly challenges the role of trastuzumab emtansine in the post-neoadjuvant residual disease setting. For clinicians, the comparison is not theoretical. It asks whether a newer HER2-directed ADC can displace an established HER2-directed ADC when the patient has already shown residual disease after initial therapy. The magnitude of invasive disease-free survival benefit gives ENHERTU a strong clinical argument, especially in high-risk patients where preventing recurrence is the central treatment priority.
However, this setting also intensifies the safety discussion. Patients receiving adjuvant treatment may already have undergone chemotherapy, surgery, radiation, and HER2-directed therapy. Adding a more potent ADC in this context requires careful management of cumulative toxicity, treatment interruptions, and discontinuations. The DESTINY-Breast05 data support efficacy, but real-world use will test whether community oncology settings can replicate safety monitoring practices seen in controlled trials.
How safety scrutiny could shape real-world uptake
The main risk that will follow ENHERTU into earlier breast cancer is interstitial lung disease and pneumonitis. The FDA label already carries a boxed warning for interstitial lung disease and embryo-fetal toxicity, and that warning becomes more consequential as the drug moves into curative-intent therapy. In DESTINY-Breast05, adjudicated drug-related interstitial lung disease or pneumonitis occurred more often with ENHERTU than with trastuzumab emtansine, including rare fatal cases.
That does not negate the efficacy signal, but it shapes how adoption will unfold. Oncologists may become more selective in patient selection, especially for individuals with pre-existing lung risk, prior radiation exposure, or clinical features that complicate pulmonary monitoring. Treatment centers will also need strong protocols for early symptom recognition, imaging, dose interruption, corticosteroid use, and discontinuation decisions. In early cancer, delayed recognition of lung toxicity can carry reputational and clinical consequences that are harder to absorb than in refractory metastatic disease.
The broader lesson for the ADC field is clear. As these drugs move earlier in cancer treatment, tolerability will become as strategically important as tumor response. Payload potency, linker technology, bystander effect, and target expression all matter, but their commercial value depends on whether physicians can use the drug safely at scale. ENHERTU’s approvals validate the upstream ADC strategy, but they also raise the industry’s safety expectations.
What this means for AstraZeneca and Daiichi Sankyo’s breast cancer strategy
For AstraZeneca and Daiichi Sankyo, the approvals strengthen ENHERTU’s position as one of the most commercially and clinically important antibody drug conjugates in oncology. The drug already has broad relevance across HER2-positive, HER2-low and HER2-ultralow breast cancer, as well as selected HER2-driven tumors beyond breast cancer. Early breast cancer expansion adds a larger strategic dimension because it places the medicine nearer to the front of the treatment pathway.
The collaboration structure also matters. Daiichi Sankyo discovered ENHERTU and remains central to manufacturing and supply, while AstraZeneca brings global oncology commercialization scale. The U.S. approvals trigger milestone payments from AstraZeneca to Daiichi Sankyo, but the larger value lies in potential long-duration revenue expansion if ENHERTU becomes embedded across multiple stages of HER2-positive breast cancer care.
Still, growth is not automatic. Earlier-stage indications can be commercially powerful, but they require guideline integration, payer confidence, clinician familiarity, and patient monitoring capacity. The inclusion of ENHERTU in oncology guideline recommendations for certain adjuvant patients supports adoption, but payers may still examine which patients derive the greatest incremental benefit. Broad use will depend on whether real-world outcomes support the trial-level risk-benefit profile.
Why regulators and clinicians will watch the next data cuts closely
The next phase of scrutiny will focus on survival maturity, recurrence patterns, lung safety, treatment completion rates, and subgroup performance. Clinicians will want to know whether the benefits are consistent across nodal status, disease burden, hormone receptor status, prior therapy intensity, and other high-risk clinical features. Regulators and payers will watch whether the therapy’s benefit remains robust as longer follow-up accumulates.
There is also a sequencing question that could become more complex. If ENHERTU is used before surgery, clinicians may need clearer guidance on what to do after surgery, especially for patients who do or do not achieve pathologic complete response. If ENHERTU is used after residual disease, oncologists will need to decide how to preserve future options if recurrence still occurs. The more successful ENHERTU becomes earlier in care, the more it may force a rethink of downstream HER2-positive breast cancer treatment algorithms.
That is a good problem for the field, but not a simple one. Oncology often advances by moving effective drugs earlier, yet each move upstream raises the burden of proof. ENHERTU has now crossed a major regulatory threshold in HER2-positive early breast cancer. The clinical community’s next decision is whether the strength of response and recurrence reduction can be translated into everyday practice without allowing safety risk to dull the promise of a potentially practice-changing ADC.
